Gennaro Ciliberto

Prof. Gennaro Ciliberto

Scientific Director IRCCS Istituto Nazionale Tumori "Regina Elena", Rome, Italy
orcid

Research Focus & Metrics

Academic Career Length

51Years (1976-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in The Lancet
Verified
Journal Article
Closed access
FPFranck Pagès
Franck Pagès
BMBernhard Mlecnik
Bernhard Mlecnik
FMFlorence Marliot
Florence Marliot
GBGabriela Bindea
Gabriela Bindea
FOFang-Shu Ou
Fang-Shu Ou
JGJerome Galon
Jerome Galon

1 January 1999 in Immunity
Verified
Journal Article
Closed access
RCRobyn Catlett-Falcone
Robyn Catlett-Falcone
TLTerry H Landowski
Terry H Landowski
MOMarc M Oshiro
Marc M Oshiro
JTJames Turkson
James Turkson
ALAlexander Levitzki
Alexander Levitzki
RJRichard Jove
Richard Jove

22 November 1996 in Science
Verified
Journal Article
Closed access
PDF file
DCDrew E. Cressman
Drew E. Cressman
LGLinda E. Greenbaum
Linda E. Greenbaum
RDRobert A. DeAngelis
Robert A. DeAngelis
Gennaro CilibertoGennaro Ciliberto
Gennaro Ciliberto
EFEmma E. Furth
Emma E. Furth
RTRebecca Taub
Rebecca Taub
Liver regeneration stimulated by a loss of liver mass leads to hepatocyte and nonparenchymal cell proliferation and rapid restoration of liver parenchyma. Mice with targeted disruption of the interleukin-6 (IL-6) gene had impaired liver regeneration characterized by liver necrosis and failure. There was a blunted DNA synthetic response in hepatocytes of these mice but not in nonparenchymal liver cells. Furthermore, there were discrete G 1 phase (prereplicative stage in the cell cycle) abnormalities including absence of STAT3 (signal transducer and activator of transcription protein 3) activation and depressed AP-1, Myc, and cyclin D1 expression. Treatment of IL-6-deficient mice with a single preoperative dose of IL-6 returned STAT3 binding, gene expression, and hepatocyte proliferation to near normal and prevented liver damage, establishing that IL-6 is a critical component of the regenerative response.

1 March 1997 in Immunity
Verified
Journal Article
Closed access
MRMaria Romano
Maria Romano
MSMarina Sironi
Marina Sironi
CTCarlo Toniatti
Carlo Toniatti
NPNadia Polentarutti
Nadia Polentarutti
PFPaolo Fruscella
Paolo Fruscella
Alberto MantovaniAlberto Mantovani
Alberto Mantovani

1 September 1996 in Circulation
Verified
Journal Article
Closed access
PDF file
LBLuigi M. Biasucci
Luigi M. Biasucci
AVAlessandra Vitelli
Alessandra Vitelli
GLGiovanna Liuzzo
Giovanna Liuzzo
SASergio Altamura
Sergio Altamura
GCGiuseppina Caligiuri
Giuseppina Caligiuri
AMAttilio Maseri
Attilio Maseri
Background Elevated plasma levels of C-reactive protein have been found in the majority of patients with unstable angina. The evidence of elevated levels of acute-phase proteins in unstable angina is in line with a growing body of evidence that suggests that inflammation plays a role in this syndrome and is an indirect sign of increased production of interleukin-6, which is the major determinant of acute-phase–protein production by the liver. However, in unstable angina, there is no direct proof of the role played by interleukin-6. Methods and Results We measured levels of interleukin-6 in 38 patients with unstable angina at the time of their admission to the coronary care unit and in 29 patients with stable angina. In the same groups of patients, we also measured C-reactive protein. Interleukin-6 (undetectable, ie, <3 pg/mL, in healthy volunteers) was detectable in 23 (61%) of 38 patients with unstable angina but in only 6 (21%) of 29 with stable angina ( P <.01). Median interleukin-6 levels were 5.25 pg/mL (range, 0 to 90 pg/mL) in patients with unstable angina but were below the detection limit of the assay in patients with stable angina (range, 0 to 7 pg/mL). A significant correlation was observed between interleukin-6 and C-reactive protein levels ( r =.4, P =.013). Conclusions Our study demonstrates that raised levels of interleukin-6 are common in unstable angina, correlate with C-reactive protein, and are associated with prognosis, thus confirming the importance of the cytokine pathway for the production by the liver of acute-phase proteins and strengthening the importance of inflammation in this syndrome. Further studies are required to elucidate better the role of interleukins in unstable angina.

16 February 1998 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
TATonino Alonzi
Tonino Alonzi
EFElena Fattori
Elena Fattori
DLDomenico Lazzaro
Domenico Lazzaro
PCPatrizia Costa
Patrizia Costa
LPLesley Probert
Lesley Probert
Gennaro CilibertoGennaro Ciliberto
Gennaro Ciliberto
Interleukin-6 (IL-6) is overproduced in the joints of patients with rheumatoid arthritis (RA) and, based on its multiple stimulatory effects on cells of the immune system and on vascular endothelia, osteoclasts, and synovial fibroblasts, is believed to participate in the development and clinical manifestations of this disease. In this study we have analysed the effect of ablating cytokine production in two mouse models of arthritis: collagen-induced arthritis (CIA) in DBA/1J mice and the inflammatory polyarthritis of tumor necrosis factor α (TNF-α) transgenic mice. IL-6 was ablated by intercrossing an IL-6 null mutation into both arthritis-susceptible genetic backgrounds and disease development was monitored by measuring clinical, histological, and biochemical parameters. Two opposite responses were observed; while arthritis in TNF-α transgenic mice was not affected by inactivation of the IL-6 gene, DBA/1J, IL-6−/− mice were completely protected from CIA, accompanied by a reduced antibody response to type II collagen and the absence of inflammatory cells and tissue damage in knee joints. These results are discussed in the light of the present knowledge of cytokine networks in chronic inflammatory disorders and suggest that IL-6 receptor antagonists might be beneficial for the treatment of RA.